You are here

P&T® Journal contents for October 2005


Inhaled corticosteroid (ICS) therapy can be associated not only with rare systemic adverse events (ADEs) but also, more commonly, with oropharyngeal ADEs. The authors investigate the economic burden of ICS treatment.
Michael Kaliner, MD; Alpesh Amin, MD, MBA, Ronald Gehling, MD, PharmD, Concetta Crivera, PharmD, Evelyn Chiao, PharmD, Tejal Vishalpura, PharmD, and Thomas Bramley, PhD
The authors examine the clinical and economic implications of PPOI within a patient population undergoing abdominal surgeries at a major urban academic medical center.
Christopher G. Salvador, PharmD, Mirko Sikirica, PharmD, Adam Evans, BS, Laura Pizzi, PharmD, MPH, and Neil Goldfarb, BA
Dr. Goldenberg discusses new indications for levofloxacin (Levaquin® Leva-pak), an antibiotic for patients with acute bacterial sinusitis and community-acquired pneumonia; valsartan (Diovan®), for left ventricular failure or left ventricular dysfunction; and dapsone gel (Aczone®), a topical therapy for acne vulgaris.
Marvin M. Goldenberg, PhD, RPh, MS
Meeting Highlights
With advances in the treatment of MI, cardiologists are now focusing on improving the safety of drugs for heart disease. The author presents some new findings on aspirin, fondaparinux, enoxaparin, heparin, clopidogrel, and fish oil for prevention and treatment.
Reuben B. David


David Nash, MD, MBA, describes the services provided by the Visiting Nurse Service of New York, which has cared for patients at home for more than a century.
David B. Nash, MD, MBA
Medication Errors
Matthew Grissinger, RPh, FASCP, explains how to avoid opiate toxicity with patient-controlled analgesia.
Matthew Grissinger, RPh, FASCP
Prescription: Washington
The Federal Trade Commission’s recent report examines PBMs and mail-order pharmacies and how Medicare drug prices will be affected by this relationship.
Stephen Barlas
P&T presents the latest studies and information about FDA approvals, drug indications, industry updates, and new devices.
Drug Forecast
The authors review erlotinib (Tarceva®) for the treatment of non–small-cell lung cancer.
Donna Clay, RPh, Yvette M. Lipman, PharmD, and Mary Ellen Bonk, PharmD